King

Antibiotic Lorabid (loracarbef) is acquired from Lilly for $90.5 mil. plus sales performance milestones bringing the total value of the deal to $158 mil. King plans to add at least 50 new sales reps to its 225-person force to help promote Lorabid along with Altace and other products. Lilly will continue to manufacture the product

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet